Skip to main content
Loading

ONL Therapeutics

February 27, 2024
Ophthalmology
ONL Therapeutics
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD.
Testimonials

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP